By Josh Beckerman
Shares of medical technology company Bluejay Diagnostics were up 82% at $11.03 Monday after a 1-for-20 reverse stock split became effective.
Volume was more than 4.9 million shares, compared with a 65-day average of 70,700.
The reverse split announced Friday morning was intended to ensure compliance with Nasdaq’s $1 minimum bid price requirement.
Bluejay’s lead product candidate is Symphony, a biomarker detection platform.
Write to Josh Beckerman at [email protected]
Read the full article here
